Literature DB >> 16891768

Blockade by NIP-142, an antiarrhythmic agent, of carbachol-induced atrial action potential shortening and GIRK1/4 channel.

Tomoyuki Matsuda1, Mie Ito, Sayoko Ishimaru, Noriko Tsuruoka, Tomoaki Saito, Naoko Iida-Tanaka, Norio Hashimoto, Toru Yamashita, Nobutomo Tsuruzoe, Hikaru Tanaka, Koki Shigenobu.   

Abstract

Mechanisms for the atria-specific action potential-prolonging action of NIP-142 ((3R*,4S*)-4-cyclopropylamino-3,4-dihydro-2,2-dimethyl-6-(4-methoxyphenylacetylamino)-7-nitro-2H-1-benzopyran-3-ol), a benzopyran compound that terminates experimental atrial arrhythmia, was examined. In isolated guinea-pig atrial tissue, NIP-142 reversed the shortening of action potential duration induced by either carbachol or adenosine. These effects were mimicked by tertiapin, but not by E-4031. NIP-142 concentration-dependently blocked the human G protein-coupled inwardly rectifying potassium channel current (GIRK1/4 channel current) expressed in HEK-293 cells with an EC50 value of 0.64 microM. At higher concentrations, NIP-142 blocked the human ether a go-go related gene (HERG) channel current with an EC50 value of 44 microM. In isolated guinea-pig papillary muscles, NIP-142 had no effect on the negative inotropic effect of carbachol under beta-adrenergic stimulation, indicating lack of effect on the muscarinic receptor and Gi protein. These results suggest that NIP-142 directly inhibits the acetylcholine-activated potassium current.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891768     DOI: 10.1254/jphs.fp0060324

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  7 in total

Review 1.  Small-molecule modulators of inward rectifier K+ channels: recent advances and future possibilities.

Authors:  Gautam Bhave; Daniel Lonergan; Brian A Chauder; Jerod S Denton
Journal:  Future Med Chem       Date:  2010-05       Impact factor: 3.808

Review 2.  Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics.

Authors:  Nipavan Chiamvimonvat; Ye Chen-Izu; Colleen E Clancy; Isabelle Deschenes; Dobromir Dobrev; Jordi Heijman; Leighton Izu; Zhilin Qu; Crystal M Ripplinger; Jamie I Vandenberg; James N Weiss; Gideon Koren; Tamas Banyasz; Eleonora Grandi; Michael C Sanguinetti; Donald M Bers; Jeanne M Nerbonne
Journal:  J Physiol       Date:  2017-01-05       Impact factor: 5.182

Review 3.  [New developments in the antiarrhythmic therapy of atrial fibrillation].

Authors:  Ursula Ravens
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2014-02-05

Review 4.  Atrial selectivity of antiarrhythmic drugs.

Authors:  Ursula Ravens; Claire Poulet; Erich Wettwer; Michael Knaut
Journal:  J Physiol       Date:  2013-06-03       Impact factor: 5.182

Review 5.  Advances in Targeting GIRK Channels in Disease.

Authors:  Yulin Zhao; Isabel Gameiro-Ros; Ian W Glaaser; Paul A Slesinger
Journal:  Trends Pharmacol Sci       Date:  2021-01-16       Impact factor: 14.819

6.  Discovery, characterization, and structure-activity relationships of an inhibitor of inward rectifier potassium (Kir) channels with preference for Kir2.3, Kir3.x, and Kir7.1.

Authors:  Rene Raphemot; Daniel F Lonergan; Thuy T Nguyen; Thomas Utley; L Michelle Lewis; Rishin Kadakia; C David Weaver; Rocco Gogliotti; Corey Hopkins; Craig W Lindsley; Jerod S Denton
Journal:  Front Pharmacol       Date:  2011-11-30       Impact factor: 5.810

7.  Characterization of VU0468554, a New Selective Inhibitor of Cardiac G Protein-Gated Inwardly Rectifying K+ Channels.

Authors:  Allison Anderson; Baovi N Vo; Ezequiel Marron Fernandez de Velasco; Corey R Hopkins; C David Weaver; Kevin Wickman
Journal:  Mol Pharmacol       Date:  2021-09-09       Impact factor: 4.436

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.